

CONTACTS

Robert White
President and Chief Executive Officer
TYRX, Inc.
732.246.8676
info@TYRX.com

TYRX Announces the Appointments of Two Industry Veterans

Monmouth Junction, NJ (September 7, 2011) – TYRX, Inc. announced today the appointments of two seasoned executives to its leadership team. Fernando Ochoa has been named Vice President of Sales. Susan Olinger has been named Vice President of Regulatory Affairs.

“Fernando and Susan bring tremendous industry experience and proven leadership, both complementing and strengthening our exceptional management team,” said Robert S. White, President and CEO. “Their deep experience in the medical device and combination products fields will enable TYRX to continue to build momentum with its unique, market leading, therapies aimed at reducing the risk of device related infections.”

Mr. Ochoa brings over 20 years of experience in the pharmaceutical, biotech, and medical device industries, including sales leadership roles with the Sorin Group, Medtronic and Genentech. Mr. Ochoa holds a BBA degree in Finance from the University of Iowa and has taken advanced courses at Benedictine University and Kellogg School of Management-Northwestern University.

Ms. Olinger has worked in the pharmaceutical and medical products industry in the United States and internationally for over 25 years. Most recently she served as a corporate Vice President of B. Braun Medical Inc., and Vice President of SAFEBT Inc., with responsibilities in preclinical, clinical, and product development and approval, involving drugs, devices, and biologics. Ms. Olinger previously held positions in regulatory and quality at Ono Pharma USA and Abbott Laboratories. She holds a BS from Wilson College, and a JD from Concord Law School.

About TYRX, Inc.

TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISR_x® Antibacterial Envelope & Flat Sheet technologies, designed to reduce surgical-site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISR_x products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in implantable pacemaker and defibrillator related endocarditis, including “superbugs” or MRSA*. Following commercial release, the AIGISR_x Envelope has been implanted in over 20,000 patients nationwide. The company estimates that over 2% of all U.S.

implantable pacemaker and defibrillator patients in 2011 will receive an AIGISR_x product during their procedure. TYRX is preparing to commercialize its second AIGISR_x technology, the AIGISR_x ST, designed to reinforce soft tissue where weakness exists and for the surgical repair of damaged or ruptured soft tissue. Current research & development projects are focusing on a fully-resorbable version of AIGISR_x.

TYRX, Inc. is an ISO 13485:2003 certified medical device manufacturer and its products utilize technology licensed exclusively from Rutgers, Baylor College of Medicine, and The University of Texas M. D. Anderson Cancer Center. For more information, please visit <http://www.tyrx.com>.

* Based upon preclinical *in vitro* and *in vivo* data. Data on file at TYRX and published in *PACE* 2009; 32(7) 898-907.

###

MKT-23-125 Rev 1